In particular, EGFR and KRAS mutations have been rarely found in the same tumours in early studies of genetic alterations in lung cancer and KRAS mutations are regarded as a biomarker of resistance to EGFR TKIs [4]. This evidence concerns the gene KRAS and lung carcinoma.